Book and coffee on table

Our Commitment to Hematology

Blood cancers and rare blood disorders account for some of the most challenging diseases to treat, and patients often have limited therapeutic options available to them. We are committed to significantly improving the health and lives of people with a range of hematologic conditions.

Across these therapeutic areas, we are focused on a number of diseases including hemophilia, cold agglutinin disease, acquired thrombotic thrombocytopenic purpura (aTTP) and multiple myeloma.

Bill Sibold, EVP and Head of Sanofi Genzyme, and John Reed, Global Head of Research & Development, share their insights on how we are drawing on our deep expertise in hematology and robust R&D programs to address numerous hematologic conditions.

Watch Sanofi's Commitment to Hematology

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.
OK